Historically, metformin and the sulfonylureas were the most-prescribed drugs for type 2 diabetes. These agents dominated the early lines of therapy until disease progression required insulin replacement. However, the emergence of more-effective, safer, and/or better-tolerated therapies, such as the dipeptidyl peptidase-4 (DPP-IV) inhibitors, sodium glucose contransporter-2 (SGLT-2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists, has provided physicians with a much broader array of therapeutic options. Moreover, because of a better understanding of type 2 diabetes and its complications, treatment is becoming more individualized. Numerous branded agents from both established and new drug classes are now jostling for position in the treatment paradigm.
- What are the trends in prescribing among recentlytreated and newly diagnosed type 2 diabetes patients?
- How have Jardiance, Trulicity, and Tresiba been integrated into the treatment algorithm?
- What proportion of type 2 diabetes patients receives drug therapy within one year of diagnosis?
- What percentage of patients progresses to later lines of therapy within one year of diagnosis?
- What percentage of type 2 diabetes patients is treated with monotherapy versus combination therapy?
- What are the most widely used combination treatments?
- What are the compliance and persistency rates for type 2 diabetes therapies?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand use across different lines of therapy using real-world patient-level claims data so that clients can accurately assess their source of business and quantify areas of opportunity for increasing their brand share.
KEY DRUGS COVERED
Afrezza, Apidra, Basaglar, Bydureon, Byetta, Farxiga, Humalog, Invokana, Januvia, Jardiance, Lantus, Levemir, Metformin, Nesina, Novolog, Onglyza, Toujeo, Tradjenta, Tresiba, Trulicity, Victoza
KEY ANALYSIS PROVIDED
- Brand use across a longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.